Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, End User, and Region - Analysis and Forecast, 2023-2033
Global Nucleic Acid Therapeutics CDMO Market Industry Overview
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033. The market is driven by factors such as the growing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases, manufacturing advancement for producing nucleic acid by CDMO (a contract development and manufacturing organization), increasing FDA(Food and Drug Administration) approvals of nucleic acid therapeutics, and increasing investment for the expansion of CDMO manufacturing units.
Market Lifecycle Stage
The global nucleic acid therapeutics CDMO market is developing. The global nucleic acid therapeutics CDMO market has witnessed several collaborations among the market players. The collaborations are aimed at combining capabilities, expanding the customer base, and marketing, among others.
The opportunity for growth of the global nucleic acid therapeutics CDMO market lies in continued research and development activities for manufacturing innovative nucleic acid therapeutics. Many pharmaceutical companies are expanding their businesses and becoming more outsourcing-oriented.
Impact of COVID-19
The COVID-19 pandemic had a low impact on the nucleic acid therapeutics contract development and manufacturing organization (CDMO) sector. The demand for nucleic acid-based COVID-19 vaccines and therapies has led to an increased demand for CDMO services. Many CDMOs have experienced an uptick in orders for services such as nucleic acid synthesis, formulation, and manufacturing of viral vectors.
The future impact of COVID-19 on the demand and supply across the global nucleic acid therapeutics CDMO market depends on the abilities of stakeholders to withstand unforeseeable scenarios in the future. The intensity of impact due to COVID-19 in the future will depend on the current efforts being made by companies to equip their supply chains with the necessary components and processes to remain responsive.
Market Segmentation:
Segmentation 1: by Product Type
- Standard Nucleic Acid
- Micro-Scale Nucleic Acid
- Large-Scale Nucleic Acid
- Custom Nucleic Acid
- Modified Nucleic Acid
- Primers
- Probes
- Other Nucleic Acid
- Other Services
- Column-Based Method
- Microarray-Based Method
Segmentation 3: By Chemical Synthesis Method
- Solid-Phase Oligonucleotide Synthesis (SPOS)
- Liquid-Phase Oligonucleotide Synthesis (LPOS)
Segmentation 4: By End User
- Pharmaceutical Companies
- Academic Research Institute
- Diagnostic Laboratories
Segmentation 5: by Region
- North America - U.S., Canada
- Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific - China, Japan, India, Australia, and Rest-of-Asia-Pacific
- Rest-of-the-World
Recent Developments in Global Nucleic Acid Therapeutics CDMO Market
- In June 2021, Danaher Corporation acquired Aldeveron for $9.6 billion. Through this acquisition, the company will expand its manufacturing capacity in plasmid DNA and mRNA.
- In January 2023, Agilent Technologies, Inc. invested $725 million to increase its manufacturing capacity for therapeutic nucleic acids.
- In March 2022, IMM, a partner of VGXI, has recently announced that it received a $12 million grant from the National Institutes of Health (NIH) to support the Phase 1 clinical trial of a DNA vaccine aimed at preventing Alzheimer's disease. The vaccine will be manufactured using VGXI's expertise in contract manufacturing of DNA plasmids for human clinical trials, produced in accordance with GMP standards.
- In April 2022, BACHEM partnered with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.
- In September 2021, AGC Biologics expanded the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
- In August 2022, Codexis and Molecular Assemblies announced the execution of a commercial license and enzyme supply agreement for an optimized TdT enzyme for enzymatic DNA synthesis.
- In June 2020, OliX Pharmaceuticals, Inc. partnered with LGC Biosearch Technologies Inc. to scale up the production of OliX’s OLX301D therapeutic candidate.
The following are the drivers for the global nucleic acid therapeutics CDMO market:
- Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
- Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
- Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
- Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
- Lack of Expertise in Developing Nucleic Acid Therapeutic
Growth/Marketing Strategy: The global nucleic acid therapeutics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.
Competitive Strategy: The global nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Companies Profiled
- Agilent Technologies, Inc.
- AGC Biologics
- Asymchem Inc.
- BACHEM
- BioCina
- CMIC HOLDINGS Co., Ltd.
- Codexis, Inc.
- Danaher Corporation
- Eurofins Scientific
- GeneOne Life Science
- Kaneka Corporation
- LGC Science Group Holdings Limited
- Maravai LifeSciences Holdings, Inc.
- Merck KGaA
- Nippon Shkubai Co., Ltd
- ST Pharm
- Thermo Fisher Scientific Inc.
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Market
- 1.1 Global Market Outlook
- 1.1.1 Market Overview
- 1.1.2 Product Definition
- 1.1.3 Inclusion and Exclusion Criteria
- 1.1.4 Key Findings
- 1.2 Industry Outlook
- 1.2.1 Key Trends
- 1.2.1.1 Significant Number of Collaborations among Market Players
- 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
- 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
- 1.2.2 Opportunity Assessment
- 1.2.3 Patent Analysis
- 1.2.3.1 Awaited Technological Developments
- 1.2.3.2 Patent Filing Trend (by Country)
- 1.2.3.3 Patent Filing Trend (by Year)
- 1.2.4 Production Capability
- 1.2.5 Regulatory Framework
- 1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
- 1.3.1 Pre-COVID-19 Phase
- 1.3.2 During COVID-19
- 1.3.3 Post-COVID-19 Phase
- 1.3.3.1 Impact on Demand and Supply
- 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
- 1.5 Significant Usage of Nucleic Acid in Therapeutics
- 1.6 Types of Nucleic Acid Synthesized for Therapeutics
- 1.6.1 Anti‐Sense Oligonucleotides (ASOs) and DNA Aptamers
- 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
- 1.6.3 MicroRNAs (miRNAs)
- 1.6.4 RNA Aptamers and RNA Decoys
- 1.6.5 Ribozymes
- 1.6.6 Circular RNAs
- 1.7 Business Dynamics
- 1.7.1 Impact Analysis
- 1.7.2 Business Drivers
- 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
- 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
- 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
- 1.7.3 Business Restraints
- 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
- 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
- 1.7.4 Business Opportunities
- 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
- 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented
- 2 Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
- 2.1 Opportunity Assessment
- 2.2 Growth-Share Matrix
- 2.3 Solid-Phase Oligonucleotide Synthesis (SPOS)
- 2.4 Liquid-Phase Oligonucleotide Synthesis (LPOS)
- 3 Global Nucleic Acid Therapeutics CDMO Market (by Product)
- 3.1 Opportunity Assessment
- 3.2 Growth-Share Matrix
- 3.2.1 Standard Nucleic Acid
- 3.2.2 Micro-Scale Nucleic Acid
- 3.2.3 Large-Scale Nucleic Acid
- 3.2.4 Custom Nucleic Acid
- 3.2.5 Modified Nucleic Acid
- 3.2.6 Primers
- 3.2.7 Probes
- 3.2.8 Other Nucleic Acid
- 3.2.9 Other Services
- 4 Global Nucleic Acid Therapeutics CDMO Market (by Technology)
- 4.1 Opportunity Assessment
- 4.2 Growth-Share Matrix
- 4.3 Column-Based Method
- 4.4 Microarray-Based Method
- 5 Global Nucleic Acid Therapeutics CDMO Market (by End Users)
- 5.1 Opportunity Assessment
- 5.2 Growth-Share Matrix
- 5.3 Pharmaceutical Companies
- 5.4 Academic Institutions
- 5.5 Diagnostic Laboratories
- 6 Global Nucleic Acid Therapeutics CDMO Market (by Region)
- 6.1 North America Nucleic Acid Therapeutics CDMO Market
- 6.1.1 Key Findings
- 6.1.2 Market Dynamics
- 6.1.2.1 Impact Analysis
- 6.1.3 Market Sizing and Forecast
- 6.1.3.1 North America Nucleic Acid Therapeutics CDMO Market (by Country)
- 6.1.3.1.1 U.S.
- 6.1.3.1.2 Canada
- 6.2 Europe Nucleic Acid Therapeutics CDMO Market
- 6.2.1 Key Findings
- 6.2.2 Market Dynamics
- 6.2.2.1 Impact Analysis
- 6.2.3 Market Sizing and Forecast
- 6.2.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
- 6.2.3.1.1 Germany
- 6.2.3.1.2 U.K.
- 6.2.3.1.3 France
- 6.2.3.1.4 Spain
- 6.2.3.1.5 Italy
- 6.2.3.1.6 Rest-of-Europe
- 6.3 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
- 6.3.1 Key Findings
- 6.3.2 Market Dynamics
- 6.3.2.1 Impact Analysis
- 6.3.3 Market Sizing and Forecast
- 6.3.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
- 6.3.3.1.1 Japan
- 6.3.3.1.2 China
- 6.3.3.1.3 India
- 6.3.3.1.4 Australia
- 6.3.3.1.5 Rest-of-Asia-Pacific
- 6.4 Rest-of-the-World Nucleic Acid Therapeutics CDMO Market
- 6.4.1 Key Findings
- 6.4.2 Market Dynamics
- 6.4.2.1 Impact Analysis
- 6.4.3 Market Sizing and Forecast
- 7 Markets - Competitive Benchmarking & Company Profiles
- 7.1 Competitive Benchmarking
- 7.1.1 Key Strategies and Developments
- 7.1.1.1 Funding Activities
- 7.1.1.2 New Offerings
- 7.1.1.3 Mergers and Acquisitions
- 7.1.1.4 Partnerships and Collaborations
- 7.1.1.5 Business Expansions
- 7.1.1.6 Regulatory and Legal Activities
- 7.1.2 Market Share Analysis
- 7.1.3 Visual Graphics of Key Companies
- 7.2 Company Profile
- 7.2.1 Agilent Technologies, Inc.
- 7.2.1.1 Company Overview
- 7.2.1.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.1.3 Financials
- 7.2.1.4 Recent Developments
- 7.2.1.5 Analyst Perspective
- 7.2.2 AGC Biologics
- 7.2.2.1 Company Overview
- 7.2.2.2 Role of AGC Biologics in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.2.3 Financials
- 7.2.2.4 Recent Developments
- 7.2.2.5 Analyst Perspective
- 7.2.3 Asymchem Inc.
- 7.2.3.1 Company Overview
- 7.2.3.2 Role of Asymchem Inc. in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.3.3 Financials
- 7.2.3.4 Recent Developments
- 7.2.3.5 Analyst Perspective
- 7.2.4 BACHEM
- 7.2.4.1 Company Overview
- 7.2.4.2 Role of BACHEM in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.4.3 Financials
- 7.2.4.4 Recent Developments
- 7.2.4.5 Analyst Perspective
- 7.2.5 BioCina
- 7.2.5.1 Company Overview
- 7.2.5.2 Role of BioCina in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.5.3 Recent Developments
- 7.2.5.4 Analyst Perspective
- 7.2.6 CMIC HOLDINGS Co., Ltd.
- 7.2.6.1 Company Overview
- 7.2.6.2 Role of CMIC HOLDINGS Co., Ltd. In the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.6.3 Financials
- 7.2.6.4 Analyst Perspective
- 7.2.7 Codexis, Inc.
- 7.2.7.1 Company Overview
- 7.2.7.2 Role of Codexis, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.7.3 Financials
- 7.2.7.4 Recent Developments
- 7.2.7.5 Analyst Perspective
- 7.2.8 Danaher Corporation
- 7.2.8.1 Company Overview
- 7.2.8.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.8.3 Financials
- 7.2.8.4 Recent Developments
- 7.2.8.5 Analyst Perspective
- 7.2.9 Eurofins Scientific
- 7.2.9.1 Company Overview
- 7.2.9.2 Role of Eurofins Scientific in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.9.3 Financials
- 7.2.9.4 Recent Developments
- 7.2.9.5 Analyst Perspective
- 7.2.10 GeneOne Life Science
- 7.2.10.1 Company Overview
- 7.2.10.2 Role of GeneOne Life Science in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.10.3 Recent Developments
- 7.2.10.4 Analyst Perspective
- 7.2.11 Kaneka Corporation
- 7.2.11.1 Company Overview
- 7.2.11.2 Role of Kaneka Corporation in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.11.3 Financials
- 7.2.11.4 Recent Developments
- 7.2.11.5 Analyst Perspective
- 7.2.12 LGC Science Group Holdings Limited
- 7.2.12.1 Company Overview
- 7.2.12.2 Role of LGC Science Group Holdings Limited in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.12.3 Recent Developments
- 7.2.12.4 Analyst Perspective
- 7.2.13 Maravai LifeSciences Holdings, Inc.
- 7.2.13.1 Company Overview
- 7.2.13.2 Role of Maravai LifeSciences Holdings, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.13.3 Financials
- 7.2.13.4 Recent Developments
- 7.2.13.5 Analyst Perspective
- 7.2.14 Merck KGaA
- 7.2.14.1 Company Overview
- 7.2.14.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.14.3 Financials
- 7.2.14.4 Recent Developments
- 7.2.14.5 Analyst Perspective
- 7.2.15 Nippon Shkubai Co., Ltd
- 7.2.15.1 Company Overview
- 7.2.15.2 Role of Nippon Shokubai Co., Ltd in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.15.3 Financials
- 7.2.15.4 Analyst Perspective
- 7.2.16 ST Pharm
- 7.2.16.1 Company Overview
- 7.2.16.2 Role of ST Pharm in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.16.3 Financials
- 7.2.16.4 Recent Developments
- 7.2.16.5 Analyst Perspective
- 7.2.17 Thermo Fisher Scientific Inc.
- 7.2.17.1 Company Overview
- 7.2.17.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
- 7.2.17.3 Financials
- 7.2.17.4 Analyst Perspective
- List of Figures
- Figure 1: Services Offered by CDMOs
- Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
- Figure 3: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
- Figure 4: Global Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
- Figure 5: Global Nucleic Acid Therapeutics CDMO Market Segmentation
- Figure 6: Global Nucleic Acid Therapeutics CDMO Market: Research Methodology
- Figure 7: Primary Research Methodology
- Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 9: Top-Down Approach (Segment-Wise Analysis)
- Figure 10: Significant Number of Collaborations among Market Players in Global Nucleic Acid Therapeutics CDMO Market, 2019-2023
- Figure 11: Core CDMO Services
- Figure 12: Global Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
- Figure 13: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
- Figure 14: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
- Figure 15: Synthesis Capabilities of Key Companies
- Figure 16: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
- Figure 17: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
- Figure 18: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
- Figure 19: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
- Figure 20: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Chemical Synthesis Method), $Billion, 2023-2033
- Figure 21: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Chemical Synthesis Method), 2022-2033
- Figure 22: Advantages and Disadvantages of Solid-Phase Oligonucleotide Synthesis
- Figure 23: Global Nucleic Acid Therapeutics CDMO Market (Solid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
- Figure 24: Advantages and Disadvantages of Liquid-Phase Oligonucleotide Synthesis
- Figure 25: Global Nucleic Acid Therapeutics CDMO Market (Liquid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
- Figure 26: Global Nucleic Acid Therapeutics CDMO Market (by Product)
- Figure 27: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Product), $Billion, 2023-2033
- Figure 28: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Product), 2022-2033
- Figure 29: Global Nucleic Acid Therapeutics CDMO Market (Standard Nucleic Acid), $Billion, 2022-2033
- Figure 30: Global Nucleic Acid Therapeutics CDMO Market (Micro-Scale Nucleic Acid), $Billion, 2022-2033
- Figure 31: Global Nucleic Acid Therapeutics CDMO Market (Large-Scale Nucleic Acid), $Billion, 2022-2033
- Figure 32: Global Nucleic Acid Therapeutics CDMO Market (Custom Nucleic Acid), $Billion, 2022-2033
- Figure 33: Global Nucleic Acid Therapeutics CDMO Market (Modified Nucleic Acid), $Billion, 2022-2033
- Figure 34: Global Nucleic Acid Therapeutics CDMO Market (Primers), $Billion, 2022-2033
- Figure 35: Global Nucleic Acid Therapeutics CDMO Market (Probes), $Billion, 2022-2033
- Figure 36: Global Nucleic Acid Therapeutics CDMO Market (Other Nucleic Acid), $Billion, 2022-2033
- Figure 37: Global Nucleic Acid Therapeutics CDMO Market (Other Services), $Billion, 2022-2033
- Figure 38: Global Nucleic Acid Therapeutics CDMO Market (by Technology)
- Figure 39: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Technology), $Billion, 2023-2033
- Figure 40: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Technology), 2022-2033
- Figure 41: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), $Billion, 2022-2033
- Figure 42: Global Nucleic Acid Therapeutics CDMO Market (Microarray-Based Method), $Billion, 2022-2033
- Figure 43: Global Nucleic Acid Therapeutics CDMO Market (by End User)
- Figure 44: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by End User), $Billion, 2023-2033
- Figure 45: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by End User), 2022-2033
- Figure 46: Global Nucleic Acid Therapeutics CDMO Market (Pharmaceutical Companies), $Billion, 2022-2033
- Figure 47: Global Nucleic Acid Therapeutics CDMO Market (Academic Institutions), $Billion, 2022-2033
- Figure 48: Global Nucleic Acid Therapeutics CDMO Market (Diagnostic Laboratories), $Billion, 2022-2033
- Figure 49: Global Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
- Figure 50: North America Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 51: North America Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
- Figure 52: U.S. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 53: Canada Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 54: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 55: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
- Figure 56: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 57: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 58: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 59: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 60: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 61: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 62: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
- Figure 63: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 64: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
- Figure 65: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 66: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 67: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 68: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 69: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 70: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
- Figure 71: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
- Figure 72: Funding Activities, January 2018-February 2023
- Figure 73: New Offerings, January 2018-February 2023
- Figure 74: Mergers and Acquisitions, January 2018-February 2023
- Figure 75: Partnerships and Collaborations, January 2018-February 2023
- Figure 76: Business Expansions, January 2018-February 2023
- Figure 77: Regulatory and Legal Activities, January 2018-February 2023
- Figure 78: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
- Figure 79: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
- Figure 80: Agilent Technologies, Inc: Product Portfolio
- Figure 81: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
- Figure 82: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 83: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 84: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 85: AGC Biologics: Product Portfolio
- Figure 86: AGC Biologics: Overall Financials, $Million, 2019-2021
- Figure 87: AGC Biologics: Segment Revenues, $Million, 2019-2021
- Figure 88: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
- Figure 89: Asymchem Inc.: Product Portfolio
- Figure 90: Asymchem Inc.: Overall Financials, $Million, 2021-2022
- Figure 91: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
- Figure 92: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
- Figure 93: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
- Figure 94: BACHEM: Product Portfolio
- Figure 95: BACHEM: Overall Financials, $Million, 2020-2022
- Figure 96: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
- Figure 97: BACHEM: Net Revenue (by Region), $Million, 2020-2022
- Figure 98: BACHEM: R&D Expenditure, $Million, 2020-2022
- Figure 99: BioCina: Product Portfolio
- Figure 100: CMIC HOLDINGS Co., Ltd.: Product Portfolio
- Figure 101: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
- Figure 102: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
- Figure 103: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
- Figure 104: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
- Figure 105: Codexis, Inc: Product Portfolio
- Figure 106: Codexis, Inc: Overall Financials, $Million, 2020-2022
- Figure 107: Codexis, Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 108: Codexis, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 109: Codexis, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 110: Danaher Corporation: Product Portfolio
- Figure 111: Danaher Corporation: Overall Financials, $Million, 2020-2022
- Figure 112: Danaher Corporation: Net Revenue (by Segment), $Million, 2020-2022
- Figure 113: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
- Figure 114: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
- Figure 115: Eurofins Scientific: Product Portfolio
- Figure 116: Eurofins Scientific: Overall Financials, $Million, 2020-2022
- Figure 117: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
- Figure 118: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
- Figure 119: VGXI, Inc.: Product Portfolio
- Figure 120: Kaneka Corporation: Product Portfolio
- Figure 121: Kaneka Corporation: Overall Financials, $Million, 2019-2021
- Figure 122: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
- Figure 123: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
- Figure 124: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
- Figure 125: LGC Science Group Holdings Limited: Product Portfolio
- Figure 126: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
- Figure 127: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
- Figure 128: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
- Figure 129: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
- Figure 130: Maravai LifeSciences Holdings, Inc.: Product Portfolio
- Figure 131: Maravai LifeSciences Holdings, Inc.: Overall Financials, $Million, 2020-2022
- Figure 132: Maravai LifeSciences Holdings, Inc.: Segment Revenues, $Million, 2020-2022
- Figure 133: Maravai LifeSciences Holdings, Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 134: Maravai LifeSciences Holdings, Inc: R&D Expenditure, $Million, 2020-2022
- Figure 135: Merck KGaA: Product Portfolio
- Figure 136: Merck KGaA: Overall Financials, $Million, 2020-2022
- Figure 137: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
- Figure 138: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
- Figure 139: Merck KGaA: R&D Expenditure, $Million, 2020-2022
- Figure 140: Nippon Shokubai Co., Ltd: Product Portfolio
- Figure 141: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
- Figure 142: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
- Figure 143: ST Pharm: Product Portfolio
- Figure 144: ST Pharm: Overall Financials, $Million, 2019-2021
- Figure 145: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021
- Figure 146: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 147: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
- Figure 148: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 149: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
- Figure 150: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
- List of Tables
- Table 1: Global Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
- Table 2: Key Questions Answered in the Report
- Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
- Table 4: Global Nucleic Acid Therapeutics CDMO Market, Key Investment
- Table 5: Global Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
- Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
- Table 7: Advancements in Manufacturing Units of CDMO
- Table 8: Companies Offering Standard Nucleic Acid
- Table 9: Companies Offering Micro-Scale Nucleic Acid
- Table 10: Companies Offering Large-Scale Nucleic Acid
- Table 11: Companies Offering Custom Nucleic Acid
- Table 12: Companies Offering Modified Nucleic Acid
- Table 13: Companies Offering Primers
- Table 14: Some of the Companies Offering Probes
- Table 15: Companies Offering Other Nucleic Acid
- Table 16: Some of the Companies Offering Other Services
- Table 17: North America Nucleic Acid Therapeutics CDMO Market, Impact Analysis
- Table 18: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
- Table 19: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis
- Table 20: Rest-of-the-World Nucleic Acid Therapeutic CDMO Market, Impact Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook